Zobrazeno 1 - 10 of 17 pro vyhledávání: '"Keeton EK"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
Autor: Hardesty MM; Alaska Women's Cancer Care, Anchorage, AK, USA. Electronic address: melissa.hardesty@akwcc.com., Krivak TC; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Western Pennsylvania Hospital, Pittsburgh, PA, USA., Wright GS; Florida Cancer Specialists and Research Institute, New Port Richey, FL, USA., Hamilton E; Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA., Fleming EL; Division of Gynecologic Oncology, Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA., Belotte J; GlaxoSmithKline, Waltham, MA, USA., Keeton EK; GlaxoSmithKline, Waltham, MA, USA at the time the analysis was conducted., Wang P; GlaxoSmithKline, Waltham, MA, USA., Gupta D; GlaxoSmithKline, Waltham, MA, USA., Clements A; Department of Gynecologic Oncology, Riverside Methodist Hospital, Columbus, OH, USA., Gray HJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA., Konecny GE; University of California, Los Angeles, Los Angeles, CA, USA., Moore RG; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA., Richardson DL; Division of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Publikováno v: Gynecologic oncology [Gynecol Oncol] 2022 Aug; Vol. 166 (2), pp. 219-229. Date of Electronic Publication: 2022 Jun 09.
Zobrazit plný text záznamu
7
Editorial & Opinion
Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208.
Autor: Tron AE; a Oncology iMed, AstraZeneca , Waltham , MA , USA., Keeton EK; a Oncology iMed, AstraZeneca , Waltham , MA , USA.; b N-of-One, Inc , Lexington , MA , USA., Ye M; a Oncology iMed, AstraZeneca , Waltham , MA , USA., Casas-Selves M; a Oncology iMed, AstraZeneca , Waltham , MA , USA.; c Drug Discovery Program, Ontario Institute for Cancer Research , Toronto , Canada., Chen H; a Oncology iMed, AstraZeneca , Waltham , MA , USA., Dillman KS; a Oncology iMed, AstraZeneca , Waltham , MA , USA., Gale RE; d Department of Haematology , University College London Cancer Institute , London , UK., Stengel C; d Department of Haematology , University College London Cancer Institute , London , UK., Zinda M; a Oncology iMed, AstraZeneca , Waltham , MA , USA., Linch DC; d Department of Haematology , University College London Cancer Institute , London , UK., Lai Z; a Oncology iMed, AstraZeneca , Waltham , MA , USA., Khwaja A; d Department of Haematology , University College London Cancer Institute , London , UK., Huszar D; a Oncology iMed, AstraZeneca , Waltham , MA , USA.; e Oncology Drug Discover Unit, Takeda Pharmaceuticals International Co , Cambridge , MA , USA.
Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2016 Dec; Vol. 57 (12), pp. 2927-2929. Date of Electronic Publication: 2016 May 17.
Zobrazit plný text záznamu
8
Akademický článek
PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Autor: Kirschner AN; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Wang J; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., van der Meer R; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Anderson PD; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Franco-Coronel OE; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Kushner MH; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Everett JH; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Hameed O; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Keeton EK; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Ahdesmaki M; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Grosskurth SE; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Huszar D; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA)., Abdulkadir SA; Department of Radiation Oncology (ANK), Department of Pathology, Microbiology and Immunology (JW, RvdM, JHE, OH, SAA), Department of Urology (OEFC), Department of Cancer Biology (SAA), Vanderbilt University Medical Center, Nashville, TN; Department of Biological Sciences, Salisbury University, Salisbury, MD (PDA); Department of Biological Sciences, Vanderbilt University, Nashville, TN (MHK); AstraZeneca, Oncology iMED, Waltham, MA (EKK, SEG, DH); AstraZeneca, R&D Information, Macclesfield, Cheshire, UK (MA); Currently at Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL (SAA). sarki.abdulkadir@northwestern.edu.
Publikováno v: Journal of the National Cancer Institute [J Natl Cancer Inst] 2014 Dec 13; Vol. 107 (2). Date of Electronic Publication: 2014 Dec 13 (Print Publication: 2015).
Zobrazit plný text záznamu
9
Akademický článek
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Autor: Keeton EK; Oncology iMed, AstraZeneca, Waltham, MA;, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, Kaur S, Wang S, Chen Y, Wu A, Shen M, Gibbons FD, Lamb ML, Zheng X, Stone RM, Deangelo DJ, Platanias LC, Dakin LA, Chen H, Lyne PD, Huszar D
Publikováno v: Blood [Blood] 2014 Feb 06; Vol. 123 (6), pp. 905-13. Date of Electronic Publication: 2013 Dec 20.
Zobrazit plný text záznamu
10
Akademický článek
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.
Autor: Dakin LA; Oncology iMed Sciences Group, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA., Block MH, Chen H, Code E, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, Keeton EK, Lamb ML, Lyne PD, Pollard H, Read J, Wu AJ, Zhang T, Zheng X
Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 Jul 15; Vol. 22 (14), pp. 4599-604. Date of Electronic Publication: 2012 Jun 06.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje